Aurora Cannabis to acquire Canadian rival MedReleaf for CA$3.2B in industry’s biggest deal

Aurora Cannabis has agreed to acquire rival Canadian hashish producer MedReleaf in a deal valued at $three.2 billion Canadian dollars ($2.5 billion) that might create the most important marijuana firm in the world.

The transaction, introduced Monday, marks the most important deal inked in the hashish sector to date, giving the mixed firm a footprint that may span 11 nations with a distribution attain into Europe, South America and Australia.

Under the deal, Edmonton-based Aurora would have the capability to produce 570,000 kilograms of hashish a yr throughout almost a dozen operations in Canada and Denmark.

Folding in MedReleaf’s quarterly gross sales of CA$11.four million, Aurora’s projected quarterly income is predicted to ring in at CA$26.1 million – simply forward of the present No. 1, Canopy Growth, which reported CA$21.7 million in income for the quarter ended Dec. 31.

“We are creating the largest cannabis producer in the world,” Aurora’s chief company officer, Cam Battley, stated throughout a convention name with reporters and buyers.

Under phrases of Monday’s deal, MedReleaf shareholders will obtain three.57 shares of Aurora for every share of MedReleaf that they maintain.

Upon completion, Aurora and MedReleaf shareholders would personal about 61% and 39% of the merged firm, respectively.

Ontario-based MedReleaf trades on the Toronto Stock Exchange as LEAF and Aurora as ACB.

The acquisition is predicted to shut by August, following shareholder and board approvals.

Consolidation underway

The megadeal is a part of a continued consolidation underway in each the hashish business and Canada, which is getting ready for authorized leisure use, anticipated later this yr.

“I think we’re going to continue to see a lot more (consolidation),” stated Alan Brochstein, a hashish business analyst and founding father of 420 Investor. “I feel now, we’re going to begin seeing offers from pharmaceutical, alcohol and tobacco corporations.

“It doesn’t take a lot of money for an institutional investor to get a toehold in the space.”

For Aurora, the deal furthers a shopping for spree it started two years in the past and most lately included:

Until the MedReleaf acquisition, Aurora’s deal with of CanniMed had been the industry’s largest.

The deal additionally alerts elevated curiosity in the hashish business from main conventional banking establishments. BMO Capital Markets served because the monetary adviser to Aurora in the deal, whereas marijuana business funding chief Canaccord Genuity suggested MedReleaf.

Company officers stated Monday that it’s too quickly to know the construction of the mixed firm’s government management.

Lisa Bernard-Kuhn might be reached at [email protected]

To enroll for our weekly Canada marijuana enterprise publication, click on right here.


Be the first to comment

Leave a Reply

Your email address will not be published.